SCHEMBL1285773

SCHEMBL1285773

Cc1nc2c(C)cc(Oc3cc(Cl)ncn3)cc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.40
KDM4E B2RXH2 1/20 0.33
PARP1 P09874 1/20 0.33
RAF1 P04049 1/20 0.32
DHODH Q02127 4/20 0.31
ALDH1A1 P00352 3/20 0.31
KMO O15229 1/20 0.31
HPGD P15428 2/20 0.30
ADORA3 P0DMS8 1/20 0.30
ADORA1 P30542 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1286182 0.89 ALDH1A1 (0.33) KDM4ERAF1ALDH1A1HPGDLMNA
SCHEMBL1709132 0.84 HTT (0.34) HTTPARP1DHODH
SCHEMBL16449127 0.84 HTT (0.36) HTTDHODH
SCHEMBL1285670 0.84 SYK (0.37) HTTKDM4ERAF1HPGD
SCHEMBL1285652 0.84 HTT (0.36) HTTKDM4EPARP1RAF1ALDH1A1
SCHEMBL1285705 0.83 CACNA1H (0.39)
SCHEMBL1285887 0.83 PTGES (0.36) PARP1ALDH1A1HPGD
SCHEMBL13351385 0.82 PRKCZ (0.34) RAF1
SCHEMBL1286076 0.81 CACNA1H (0.41) ALDH1A1
SCHEMBL1285598 0.80 DRD1 (0.38) KDM4EPARP1RAF1KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379529-B1 CGRP-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-06-10 EP disclosed
EP-2379529-B1 CGRP-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-06-10 EP disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 US disclosed
EP-2379529-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-26 EP disclosed
WO-2010070022-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-06-24 WO disclosed
WO-2010070022-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088755-A1 Novel Compounds SLC26A4, F12, SLCO1B3 HTT 2370/4885KDM4E 4588/4885PARP1 3129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.